Ibrutinib and Zanubrutinib Q&A
May 9 @ 12:00 pm - 1:00 pm
We know that the recent NICE decisions about the drugs ibrutinib and zanubrutinib are a cause for worry for many in the WM community. Our CEO, Jane Nicholson, who has been working with NICE and the drug companies involved during the processes join us for a Q&A session about what the decisions mean for you, and what comes next.
Can’t make this session? We’ll be repeating the session on Thursday at 8pm. Register here.